Gastroenterology
Volume 141, Issue 6 , Pages 2210-2217.e2 , December 2011

Intra-acinar Trypsinogen Activation Mediates Early Stages of Pancreatic Injury but Not Inflammation in Mice With Acute Pancreatitis

Received 2 June 2011 ,Accepted 18 August 2011.

References 

  1. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379–2400
  2. Fagenholz PJ, Fernandez-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas. 2007;35:302–307
  3. Chiari H. ÜberdieSelbstverdauung des menschlichenPankreas. ZeitschriftfürHeilkunde. 1896;17:69–96
  4. Hofbauer B, Saluja AK, Lerch MM, et al. Intra-acinar cell activation of trypsinogen during caerulein-induced pancreatitis in rats. Am J Physiol. 1998;275:G352–G362
  5. Saluja AK, Bhagat L, Lee HS, et al. Secretagogue-induced digestive enzyme activation and cell injury in rat pancreatic acini. Am J Physiol. 1999;276:G835–G842
  6. Saluja A, Saluja M, Villa A, et al. Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal enzyme colocalization. J Clin Invest. 1989;84:1260–1266
  7. Saluja AK, Donovan EA, Yamanaka K, et al. Cerulein-induced in vitro activation of trypsinogen in rat pancreatic acini is mediated by cathepsin B. Gastroenterology. 1997;113:304–310
  8. Saluja AK, Lerch MM, Phillips PA, et al. Why does pancreatic overstimulation cause pancreatitis?. Annu Rev Physiol. 2007;69:249–269
  9. Lerch MM, Gorelick FS. Early trypsinogen activation in acute pancreatitis. Med Clin North Am. 2000;84:549–563viii
  10. Grady T, Mah'Moud M, Otani T, et al. Zymogen proteolysis within the pancreatic acinar cell is associated with cellular injury. Am J Physiol. 1998;275:G1010–G1017
  11. Kloppel G, Dreyer T, Willemer S, et al. Human acute pancreatitis: its pathogenesis in the light of immunocytochemical and ultrastructural findings in acinar cells. Virchows Arch A Pathol Anat Histopathol. 1986;409:791–803
  12. Willemer S, Kloppel G, Kern HF, et al. Immunocytochemical and morphometric analysis of acinar zymogen granules in human acute pancreatitis. Virchows Arch A Pathol Anat Histopathol. 1989;415:115–123
  13. Gorelick FS, Thrower E. The acinar cell and early pancreatitis responses. Clin Gastroenterol Hepatol. 2009;7(11 Suppl):S10–S14
  14. Singh VP, Saluja AK, Bhagat L, et al. Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis. J Clin Invest. 2001;108:1387–1395
  15. Watanabe O, Baccino FM, Steer ML, et al. Supramaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis. Am J Physiol. 1984;246:G457–G467
  16. Lerch MM, Saluja AK, Dawra R, et al. The effect of chloroquine administration on two experimental models of acute pancreatitis. Gastroenterology. 1993;104:1768–1779
  17. Halangk W, Lerch MM, Brandt-Nedelev B, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest. 2000;106:773–781
  18. Van Acker GJ, Saluja AK, Bhagat L, et al. Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. Am J Physiol Gastrointest Liver Physiol. 2002;283:G794–G800
  19. Hietaranta AJ, Saluja AK, Bhagat L, et al. Relationship between NF-kappaB and trypsinogen activation in rat pancreas after supramaximal caerulein stimulation. Biochem Biophys Res Commun. 2001;280:388–395
  20. Van Acker GJ, Weiss E, Steer ML, et al. Cause-effect relationships between zymogen activation and other early events in secretagogue-induced acute pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1738–G1746
  21. Kereszturi E, Sahin-Toth M. Intracellular autoactivation of human cationic trypsinogen mutants causes reduced trypsinogen secretion and acinar cell death. J Biol Chem. 2009;284:33392–33399
  22. Ji B, Gaiser S, Chen X, et al. Intracellular trypsin induces pancreatic acinar cell death but not NF-kappaB activation. J Biol Chem. 2009;284:17488–17498
  23. Gaiser S, Ahler A, Gundling F, et al. Expression of mutated cationic trypsinogen reduces cellular viability in AR4-2J cells. Biochem Biophys Res Commun. 2005;334:721–728
  24. Whitcomb DC. Genetic aspects of pancreatitis. Annu Rev Med. 2010;61:413–424
  25. Teich N, Rosendahl J, Toth M, et al. Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum Mutat. 2006;27:721–730
  26. Singh VP, Chari ST. Protease inhibitors in acute pancreatitis: lessons from the bench and failed clinical trials. Gastroenterology. 2005;128:2172–2174
  27. Singh VP, Bren GD, Algeciras-Schimnich A, et al. Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1040–G1046
  28. Simon P, Weiss FU, Sahin-Toth M, et al. Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 → Cys) that alters autoactivation and autodegradation of cationic trypsinogen. J Biol Chem. 2002;277:5404–5410
  29. Kukor Z, Mayerle J, Kruger B, et al. Presence of cathepsin B in the human pancreatic secretory pathway and its role in trypsinogen activation during hereditary pancreatitis. J Biol Chem. 2002;277:21389–21396
  30. Wartmann T, Mayerle J, Kahne T, et al. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology. 2010;138:726–737
  31. Halangk W, Kruger B, Ruthenburger M, et al. Trypsin activity is not involved in premature, intrapancreatic trypsinogen activation. Am J Physiol Gastrointest Liver Physiol. 2002;282:G367–G374
  32. Li W, Nakagawa T, Koyama N, et al. Down-regulation of trypsinogen expression is associated with growth retardation in alpha1,6-fucosyltransferase-deficient mice: attenuation of proteinase-activated receptor 2 activity. Glycobiology. 2006;16:1007–1019
  33. Roach JC, Wang K, Gan L, et al. The molecular evolution of the vertebrate trypsinogens. J Mol Evol. 1997;45:640–652
  34. Ozsvari B, Hegyi P, Sahin-Toth M. The guinea pig pancreas secretes a single trypsinogen isoform, which is defective in autoactivation. Pancreas. 2008;37:182–188
  35. Chen JM, Ferec C. Chronic pancreatitis: genetics and pathogenesis. Annu Rev Genomics Hum Genet. 2009;10:63–87
  36. Watanabe T, Ogasawara N. Purification and properties of multiple forms of mouse trypsinogen. Biochim Biophys Acta. 1982;717:439–444
  37. Watanabe T. Purification and properties of genetic variants of mouse trypsinogen. Biochem Genet. 1983;21:761–772
  38. Isobe M, Ogita Z. Electrophoretic analysis of pancreatic proteases and zymogen-activating factors in the mouse. J Exp Zool. 1984;230:347–354
  39. Canbay A, Guicciardi ME, Higuchi H, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest. 2003;112:152–159
  40. Kukor Z, Toth M, Pal G, et al. Human cationic trypsinogen (Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation). J Biol Chem. 2002;277:6111–6117
  41. Kukor Z, Toth M, Sahin-Toth M. Human anionic trypsinogen: properties of autocatalytic activation and degradation and implications in pancreatic diseases. Eur J Biochem. 2003;270:2047–2058
  42. Koshikawa N, Yasumitsu H, Nagashima Y, et al. Identification of one- and two-chain forms of trypsinogen 1 produced by a human gastric adenocarcinoma cell line. Biochem J. 1994;303:187–190
  43. Chen JM, Ferec C. Genes, cloned cDNAs, and proteins of human trypsinogens and pancreatitis-associated cationic trypsinogen mutations. Pancreas. 2000;21:57–62
  44. Guy O, Lombardo D, Bartelt DC, et al. Two human trypsinogens (Purification, molecular properties, and N-terminal sequences). Biochemistry. 1978;17:1669–1675
  45. Rinderknecht H, Renner IG, Carmack C. Trypsinogen variants in pancreatic juice of healthy volunteers, chronic alcoholics, and patients with pancreatitis and cancer of the pancreas. Gut. 1979;20:886–891
  46. Rinderknecht H, Stace NH, Renner IG. Effects of chronic alcohol abuse on exocrine pancreatic secretion in man. Dig Dis Sci. 1985;30:65–71
  47. Barrett KE, Barman SM, Boitano S, et al. Protein digestion. In: Barrett KE, Barman SM, Boitano S, et al, eds. Ganong's review of medical physiology http://www.accessmedicine.com/content.aspx?aID=5242356
  48. Gukovsky I, Gukovskaya AS, Blinman TA, et al. Early NF-kappaB activation is associated with hormone-induced pancreatitis. Am J Physiol. 1998;275:G1402–G1414
  49. Rakonczay Z, Hegyi P, Takacs T, et al. The role of NF-kappaB activation in the pathogenesis of acute pancreatitis. Gut. 2008;57:259–267
  50. Han B, Ji B, Logsdon CD. CCK independently activates intracellular trypsinogen and NF-kappaB in rat pancreatic acinar cells. Am J Physiol Cell Physiol. 2001;280:C465–C472
  51. Tando Y, Algul H, Schneider G, et al. Induction of IkappaB-kinase by cholecystokinin is mediated by trypsinogen activation in rat pancreatic lobules. Digestion. 2002;66:237–245
  52. Gaiser S, Daniluk J, Liu Y, et al. Intracellular activation of trypsinogen in transgenic mice induces acute but not chronic pancreatitis. Gut. 2011;60:1379–1388
  53. Chen X, Ji B, Han B, et al. NF-kappaB activation in pancreas induces pancreatic and systemic inflammatory response. Gastroenterology. 2002;122:448–457
  54. Baumann B, Wagner M, Aleksic T, et al. Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo. J Clin Invest. 2007;117:1502–1513
  55. Altavilla D, Famulari C, Passaniti M, et al. Attenuated cerulein-induced pancreatitis in nuclear factor-kappaB-deficient mice. Lab Invest. 2003;83:1723–1732
  56. Tando Y, Algul H, Wagner M, et al. Caerulein-induced NF-kappaB/Rel activation requires both Ca2+ and protein kinase C as messengers. Am J Physiol. 1999;277:G678–G686
  57. Algul H, Treiber M, Lesina M, et al. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J Clin Invest. 2007;117:1490–1501
  58. Aleksic T, Baumann B, Wagner M, et al. Cellular immune reaction in the pancreas is induced by constitutively active IkappaB kinase-2. Gut. 2007;56:227–236
  59. Witt H, Sahin-Toth M, Landt O, et al. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet. 2006;38:668–673
  60. Itkonen O. Human trypsinogens in the pancreas and in cancer. Scand J Clin Lab Invest. 2010;70:136–143

 Conflicts of interest The authors disclose no conflicts.

 Funding Supported in part by National Institutes of Health grants RO1 DK058694, RO1 DK 092145, and RO1 DK093047 (to A.K.S.).

PII: S0016-5085(11)01216-9

doi: 10.1053/j.gastro.2011.08.033

Gastroenterology
Volume 141, Issue 6 , Pages 2210-2217.e2 , December 2011

Article Tools

* Image Usage & Resolution